The development of inhibitors that target TGFβ signaling is a promising treatment approach for cancers where TGFβ promotes tumor growth and metastasis (Derynck and Akhurst, 2007; Herbertz et al., 2015). The gene discussed is TGFB1; the disease is neoplasm.